✦ LIBER ✦

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

✍ Scribed by Anja Strangfeld, Franka Hierse, Rolf Rau…

Book ID: 120705652
Publisher: BioMed Central
Year: 2010
Tongue: English
Weight: 735 KB
Volume: 12
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar2904

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk of septic arthritis in patients wit

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

✍ Galloway, J. B.; Hyrich, K. L.; Mercer, L. K.; Dixon, W. G.; Ustianowski, A. P.; 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 158 KB

Association between anti-tumour necrosis

Association between anti-tumour necrosis factor therapy and risk of ischaemic stroke in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA)

✍ Low, Audrey SL; Lunt, Mark; Mercer, Louise K; Galloway, James B; Davies, Rebecca 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 47 KB

Influence of anti–tumor necrosis factor

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

✍ W. G. Dixon; K. D. Watson; M. Lunt; L. K. Mercer; British Society For Rheumatolo 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 111 KB 👁 2 views

Reduction in the incidence of myocardial

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

✍ W. G. Dixon; K. D. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods